New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on... | May 25, 2023
United States France General Fabreguettes Leib Shahram Attarian University Hospital La Timone Rare Diseases Network
Source: marketscreener.com